Compare FSBW & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FSBW | ALEC |
|---|---|---|
| Founded | 1936 | 2013 |
| Country | United States | United States |
| Employees | 537 | N/A |
| Industry | Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 332.6M | 275.8M |
| IPO Year | 2011 | 2019 |
| Metric | FSBW | ALEC |
|---|---|---|
| Price | $44.35 | $2.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 7 |
| Target Price | ★ $45.50 | $3.90 |
| AVG Volume (30 Days) | 24.3K | ★ 4.6M |
| Earning Date | 10-21-2026 | 11-13-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.07 | N/A |
| Revenue | $4,612,000.00 | ★ $21,045,000.00 |
| Revenue This Year | $5.22 | $214.33 |
| Revenue Next Year | $9.03 | N/A |
| P/E Ratio | $21.12 | ★ N/A |
| Revenue Growth | ★ 44.80 | N/A |
| 52 Week Low | $36.66 | $1.09 |
| 52 Week High | $45.85 | $2.76 |
| Indicator | FSBW | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 51.03 | 55.88 |
| Support Level | $43.30 | $2.02 |
| Resistance Level | $44.26 | $2.65 |
| Average True Range (ATR) | 0.97 | 0.17 |
| MACD | -0.07 | 0.04 |
| Stochastic Oscillator | 64.35 | 68.33 |
FS Bancorp Inc is the holding company of First Security Bank, a diversified lender with a focus on the origination of commercial real estate, one-to-four-family, and home equity loans, consumer loans, including a variety of indirect home improvement (fixture secured loans), and marine loans, and commercial business loans. The company has two operating segments; The commercial and consumer banking segment provides diversified financial products and services to its commercial and consumer customers through Bank branches, automated teller machines, online banking platforms, mobile banking apps, and telephone banking; and The home lending segment originates one-to-four-family residential mortgage loans for sale in the secondary markets as well as loans held for investment.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.